



A pyrene based fluorescence approach to study conformation of apolipoprotein E3 in macrophage-generated nascent high density lipoprotein



Sea H. Kim^a, Shweta Kothari^a, Arti B. Patel^a, John K. Bielicki^b, Vasanthy Narayanaswami^{a,*}

^a Department of Chemistry & Biochemistry, California State University Long Beach, Long Beach, CA 90840, USA

^b Life Sciences Division, Lawrence Berkeley National Laboratory, University of California, Berkeley, Berkeley, CA 94720, USA

ARTICLE INFO

Article history:

Received 12 May 2014

Available online 24 May 2014

Keywords:

Macrophage

Apolipoprotein E3

Nascent HDL

Pyrene fluorescence

Cross-linking

Reverse cholesterol transport

ABSTRACT

Apolipoprotein E3 (apoE3) is an anti-atherogenic apolipoprotein with the ability to exist in lipid-free and lipoprotein-associated states. During atherosclerosis, its function in promoting cholesterol efflux from macrophages via the ATP-binding cassette transporter A1 (ABCA1) takes a prominent role, leading to generation of nascent high density lipoprotein (nHDL) particles. The objective of this study is to understand the conformation adopted by apoE3 in macrophage-generated nHDL using a fluorescence spectroscopic approach involving pyrene. Pyrene-labeled recombinant human apoE3 displayed a robust ability to stimulate ABCA1-mediated cholesterol efflux from cholesterol-loaded J774 macrophages (which do not express apoE), comparable to that elicited by unlabeled apoE3. The nHDL recovered from the conditioned medium revealed the presence of apoE3 by immunoblot analysis. A heterogeneous population of nHDL bearing exogenously added apoE3 was generated with particle size varying from ~12 to ~19 nm in diameter, corresponding to molecular mass of ~450 to ~700 kDa. The lipid: apoE3 ratio varied from ~60:1 to 10:1. A significant extent of pyrene excimer emission was noted in nHDL, indicative of spatial proximity between Cys112 on neighboring apoE3 molecules similar to that noted in reconstituted HDL. Cross-linking analysis using Cys-specific cross-linkers revealed the predominant presence of dimers. Taken together the data indicate a double belt arrangement of apoE molecules on nHDL. A similar organization of the C-terminal tail of apoE on nHDL was noted when pyrene-apoEA277C(201–299) was used as the cholesterol acceptor. These studies open up the possibility of using exogenously labeled apoE3 to generate nHDL for structural and conformational analysis.

© 2014 Elsevier Inc. All rights reserved.

1. Introduction

The role of apoE3 in regulating plasma cholesterol homeostasis and as an anti-atherogenic agent is mediated by its ability to serve as a ligand for the LDL receptor family of proteins [1–3]. This facilitates cellular internalization of lipoproteins [4], thereby lowering plasma cholesterol levels. During atherosclerosis, apoE also functions in reverse cholesterol transport, which involves transport of cholesterol from peripheral tissues to liver via high density lipoproteins (HDL); under normal physiological conditions, this role

is attributed to apolipoprotein AI (apoAI), a major exchangeable component of HDL [5]. However, in atherosclerosis apoE3 plays a dominant role with macrophages secreting large amounts of (lipid-free or lipid-poor) apoE3, which in turn presumably promotes cholesterol efflux via ATP-binding cassette transporter A1 (ABCA1) as a protective mechanism, with a resultant formation of nascent HDL (nHDL) containing apoE3 [6–8].

ApoE3 is composed of several amphipathic α -helices that are folded into an N-terminal domain (1–191) and a C-terminal domain (201–299) bearing high affinity binding sites for lipids [9]. In the lipid-free state, the former is folded as a 4-helix bundle wherein the hydrophobic face of each helix is sequestered towards the protein interior and the hydrophilic face is oriented towards the aqueous environment [10]. The amphipathic helices in the C-terminal domain mediate inter-molecular helix–helix interactions and protein tetramerization [11,12].

Abbreviations: ABCA1, ATP-binding cassette transporter A1; ApoE3, apolipoprotein E3; nHDL, nascent high density lipoprotein; POPC, palmitoylphosphatidylcholine; rHDL, reconstituted high density lipoprotein.

* Corresponding author. Address: Department of Chemistry & Biochemistry, 1250 Bellflower Blvd, California State University Long Beach, Long Beach, CA 90840, USA. Fax: +1 562 985 8557.

E-mail address: vas.narayanaswami@csulb.edu (V. Narayanaswami).

As exchangeable apolipoproteins, both apoAI and apoE3 exhibit the capability to exist in lipid-free and lipoprotein-bound states, with a conformational change accompanying the transition between the two states. Several biophysical approaches indicate that reconstitution of HDL using apoAI and synthetic phospholipids (typically DMPC or POPC) and cholesterol results in the protein adopting a double belt-like organization of α -helices circumscribing a bilayer of phospholipids [5,13,14]. Much less is known about the organization of lipid-associated apoE3 although the available data suggest a similar organization in reconstituted HDL (rHDL) [15–18]. While this “bottom-up” approach has yielded significant information regarding the functional organization of apolipoproteins, knowledge regarding their conformation in nHDL generated by macrophages is lacking. In this study, we adopt a “top-down” approach to investigate the conformation of exogenously added human apoE3 in nHDL by allowing J774 macrophages (which do not synthesize apoE) to assemble the lipoprotein particle in an ABCA1-dependent process. Other groups employing this approach used radiolabeled-apoAI or -lipids (due to the small amounts of HDL generated by macrophages) to study the functional composition of nHDL [19]. In the present study, we use single Cys containing apoE3 or its isolated C-terminal domain to study their organization in macrophage-assembled nHDL using a combination of spectroscopic and cross-linking approach.

2. Materials and methods

2.1. Purification of apoE3 and apoE(201–299)

Recombinant human apoE3(1–299) or apoE(201–299) with a hexa-His tag at the N-terminal end was purified as described previously [12]. ApoE(201–299) bears a single substituted cysteine at position 277 to enable labeling with an exogenous probe. Protein concentration was determined in a Nano-Drop spectrometer using molar extinction coefficient at 280 nm ($44,460 \text{ M}^{-1} \text{ cm}^{-1}$ for apoE3(1–299) and $16,500 \text{ M}^{-1} \text{ cm}^{-1}$ for apoE(201–299)).

2.2. Labeling with N-(1-pyrene)maleimide (NPM)

The naturally occurring single Cys112 in apoE3 and the substituted single cysteine in apoE(201–299) (A277C) were used to label with NPM [12,20]. The pyrene (pyr)-labeled sample was dialyzed against 10 mM sodium phosphate, pH 7.4, 150 mM NaCl (phosphate buffered saline, PBS). The stoichiometry of labeling was calculated to be ~ 1.0 using the molar extinction coefficient of pyrene at 345 nm in methanol ($40,000 \text{ M}^{-1} \text{ cm}^{-1}$).

2.3. Biogenesis of nHDL containing apoE3 or apoE(201–299)

J774 mouse macrophages were grown in RPMI-1640 with 1% FBS for 48 h as described previously [21,22]. Cells from a confluent culture were plated with a 1:10 dilution onto twelve T175 flasks and exposed to 0.3 mM cAMP analogue (cpt-cAMP) for 18 h to up-regulate ABCA1 expression. They were rinsed extensively, and then exposed to $10 \mu\text{g/ml}$ of unlabeled or pyrene-labeled apoE3 or apoEA277C(201–299) in serum-free medium for 18 h. The conditioned medium (250 ml) was filtered through $0.45 \mu\text{m}$ PVDF membrane filter, and concentrated in a 10-kDa cut-off Amicon filter. Lipid-bound protein was separated from unbound protein by density gradient ultracentrifugation ($435,000 \times g$, 5.5 h) using a KBr gradient (density range between 1.063 and 1.21 g/ml) as described previously [23] (0.5 g KBr/ml). About 10 fractions were collected and those containing both protein and lipid were pooled and concentrated. Under the conditions employed, fractions corresponding to the density range 1.10–1.13 g/ml are referred to as

‘Top’ (typically fractions 1–4) and those in 1.14–1.17 g/ml range as ‘Mid’ fractions (typically fractions 5–7) (designated based on identical conditions using PBS). The protein content of the lipoprotein complexes was measured using the DC^{TM} protein assay kit (BioRad Laboratories, Hercules, CA).

2.4. Preparation of rHDL containing apoE3 or apoE(201–299)

rHDL containing unlabeled or pyrene-labeled apoE3 or apoEA277C(201–299), and, POPC or POPC/cholesterol was prepared by the cholate dialysis method with slight modifications [17]. Briefly, $\sim 10 \text{ mg}$ sodium deoxycholate was added to a thin film of POPC (10 mg) or POPC/cholesterol (between 10:1 and 1:1 ratio phospholipid: cholesterol, total lipid $\sim 10 \text{ mg}$) in 1 ml PBS, vortexed until clear, incubated for 2 h with 1 ml of apoE (4 mg/ml) at 37°C for 1 h and dialyzed extensively at 4°C . Lipid-bound protein was isolated by density gradient ultracentrifugation and, characterized in terms of particle size and diameter. The protein and phospholipid content of rHDL was measured as described above; cholesterol content (both free cholesterol and cholesteryl ester, CE) was measured using the Amplex[®] Red kit (Life Technologies, Grand Island, NY).

2.5. Western blot

The nHDL and rHDL samples were electrophoresed on a SDS-PAGE 4–20% acrylamide gradient Tris-glycine gel and visualized by Western blot using goat anti-apoE-HRP antibody. The intact complexes were observed by electrophoresis for 20 h at 45 V under non-denaturing conditions using $\sim 5 \mu\text{g}$ sample, followed by Western blot; the molecular mass and average particle size were determined using Amersham High Molecular Weight Standards.

2.6. Fluorescence measurements

Steady state fluorescence analyses were performed on a Perkin-Elmer LS55B fluorometer at 24°C . Fluorescence emission spectra of pyrene-labeled samples ($\sim 10 \mu\text{g}$) were recorded between 350 and 550 nm (excitation at 345 nm, excitation and emission slit-widths at 5 nm, and the scan speed at 50 nm/min).

2.7. Cross-linking

The nHDL and rHDL samples ($1\text{--}10 \mu\text{g}$) were incubated with 5-fold molar excess of tris(2-carboxyethyl)phosphine at 24°C for 30 min, followed by treatment with increasing concentrations of 1,6-bismaleimidohehexane (BMH) (0-, 25-, 50-, 100-fold molar excess over protein) at 24°C for 1 h. The cross-linked species were electrophoresed under denaturing, reducing conditions and visualized by Western blot.

3. Results and discussion

Pyr-apoE3 stimulated a robust ABCA1-dependent [^3H]-cholesterol efflux in J774 macrophages, comparable to that of unlabeled protein, Fig. 1A; the stimulation was dose-dependent at the concentrations used (5, 10 and $20 \mu\text{g}$ labeled protein/ml), Fig. 1B. This indicates that the presence of the covalently attached exogenous probe, added for subsequent spectroscopic measurements, does not alter the functional ability of the protein. Previous studies have shown that the C-terminal domain of apoE3 encompassing residues 222–299 was necessary and sufficient to promote efficient ABCA1-mediated cholesterol efflux [21]. In the current study, we confirmed that apoE(201–299) served as an efficient acceptor of




Fig. 1. $[^3\text{H}]$ Cholesterol efflux mediated by unlabeled, pyr-apoE3 or apoE(201–299). (A) J774 macrophages were labeled with $[^3\text{H}]$ cholesterol (1 $\mu\text{Ci}/\text{mL}$) in RPMI-1640 with 1% FBS for 48 h. ABCA1 expression was up-regulated for 18 h with cpt-cAMP, followed by exposure to 10 $\mu\text{g}/\text{mL}$ unlabeled or pyr-apoE3 in serum-free RPMI-1640 medium. The amount of $[^3\text{H}]$ cholesterol appearing in the medium after 4 h was expressed as % of the radioactivity present in cells at time zero. A parallel experiment with no cpt-cAMP was conducted to assess efflux in the absence of ABCA1 up-regulation. Background release of $[^3\text{H}]$ cholesterol to serum-free medium was subtracted from values obtained with added proteins. Values are mean \pm SD, $n = 3$. (B) Dose-dependent (5, 10 and 20 $\mu\text{g}/\text{mL}$) efflux for unlabeled apoE3 or pyr-apoE3. (C) ABCA1-mediated cholesterol efflux promoted by apoE(201–299). All conditions employed were as described above except that the amount of $[^3\text{H}]$ cholesterol appearing in the medium was followed 8 h after addition of 3 $\mu\text{g}/\text{mL}$ apoE(201–299) as acceptor in the absence or presence of cpt-cAMP. Values are mean \pm SD, $n = 3$. (D) Dose-dependent cholesterol efflux (0.1–10 $\mu\text{g}/\text{mL}$) promoted by apoE(201–299). Data shown are representative of 2 independent experiments.

cholesterol efflux, Fig. 1C, with the stimulation being dose dependent as well, Fig. 1D.

These initial experiments laid the groundwork for subsequent studies using larger culture volumes bearing non-radioactive cholesterol for biophysical analysis. Following efflux, lipid-associated unlabeled or pyr-apoE3 was separated from lipid-free protein in the conditioned medium. The presence of apoE3 (in Top and Mid fractions) was confirmed by Western blot, Fig. 2A. Unlabeled apoE3 in rHDL reconstituted with POPC is shown for comparison. Fig. 2B shows nHDL bearing unlabeled apoE(201–299) or pyr-apoEA277C(201–299) (only the Top fraction) and the corresponding rHDL that were isolated as described above.

The intact nHDL bearing unlabeled or labeled apoE3 was observed by Western blot under non-denaturing conditions (Fig. 2C, lanes 1–4). In both cases, a heterogeneous pool of nHDL particles was observed in the Top and Mid fractions; the mass varied from 450 to 700 kDa (12–17 nm diameter); in addition, a minor population with molecular mass ~ 250 kDa (9 nm diameter) was observed in the Mid fraction containing apoE3. The lipid: protein ratio in the Top and Mid fractions was found to be 60:1 and 10:1, respectively; the presence of the probe did not affect this ratio. Similarly, rHDL samples (Fig. 2C) containing POPC and apoE3 also contained large diameter particles (lane 5), while those containing POPC, cholesterol and apoE3 (lane 6) revealed the additional presence of smaller diameter (8–9 nm) particles. The molecular mass and average diameter of the nHDL particles bearing unlabeled or pyrene-labeled apoE(201–299), (Fig. 2D, lanes 1 and 2, respectively) were found to be 140–700 kDa range corresponding to 8–17 nm particle diameter. For comparison, rHDL bearing POPC, cholesterol and unlabeled or pyrene-labeled apoE(201–299) is shown, Fig. 2D, lanes 3 and 4, respectively. Their mass ranged from 450 to 700 kDa corresponding to 12–17 nm diameter. We did not detect any significant CE in these nHDL, regardless of the presence or absence of C-terminal domain or pyrene label.

Having established the lipid-associated state of pyr-apoE3 in nHDL, its organization was evaluated by comparing the fluorescence emission spectra with that of lipid-free protein. NPM was the fluorophore of choice because: (i) it has a high molar extinction coefficient, which enables us to employ physiologically relevant amounts of labeled protein, which is often not the case in spectroscopic measurements; (ii) it offers information regarding spatial




Fig. 2. Western blot analysis of nHDL and rHDL containing apoE3 or apoE(201–299). (A) SDS-PAGE of apoE3 containing nHDL and rHDL. The nHDL samples containing unlabeled (lanes 1 and 2) or pyr-apoE3 (lanes 3 and 4) (1 μg protein) were electrophoresed on a SDS-PAGE gel under reducing conditions. Lanes 1 and 3 represent Top, while lanes 2 and 4 represent the Mid fractions. Unlabeled apoE3 in rHDL (POPC/apoE3) is shown for comparison (lane 5). ApoE was detected using apoE-HRP antibody. (B) SDS-PAGE of apoE(201–299) containing nHDL and rHDL. nHDL containing apoE(201–299) (lane 1) or pyr-apoEA277C(201–299) (lane 2) were electrophoresed as described under A and detected with 3H1 as the primary antibody. Unlabeled apoEA277C(201–299) in rHDL reconstituted with POPC is shown for comparison (lane 3). (C) Non-denaturing PAGE of apoE3 containing nHDL and rHDL. The nHDL samples containing unlabeled (lanes 1 and 2) or pyr-apoE3 (lanes 3 and 4) (5 μg protein) were electrophoresed under non-denaturing conditions. Lanes 1 and 3 represent Top, while lanes 2 and 4 represent the Mid fractions. Unlabeled apoE in rHDL reconstituted with POPC (lane 5) or POPC/cholesterol (lane 6) are shown for comparison. (D) Non-denaturing PAGE of apoE(201–299) containing nHDL and rHDL. nHDL containing apoE(201–299) (lane 1) or pyr-apoEA277C(201–299) (lane 2) were electrophoresed as described under C and visualized as in B. Unlabeled and pyr-apoEA277C(201–299) in rHDL reconstituted with POPC are shown for comparison (lanes 3 and 4, respectively). The Stokes' diameter of the standards shown in C and D (from high to low) are 17, 12.2, 9.2 and 8.1 nm.

proximity, exhibiting featureless excimer emission at ~ 460 nm when two pyrene moieties are ~ 10 Å from each other; this is in addition to the monomeric fluorescence emission (an ensemble of 5 major vibronic bands), corresponding to peaks at ~ 375 , 379, 385, 395 and 405 nm, and, (iii) the peak at 385 nm is exquisitely sensitive to the polarity of the probe's microenvironment, which offers definitive information about the lipid-associated state of the protein. The appearance of a higher 385 nm emission peak (compared to 375 nm) is indicative of a hydrophobic microenvironment in the probe vicinity [24,25].

Lipid-free pyr-apoE3 shows a strong excimer emission indicative of ~ 10 Å proximity between C112 in neighboring monomeric units in a tetramer, Fig. 3A (a). Significant excimer emission was noted in both Top (b) and Mid (c) fractions of nHDL, suggesting ~ 10 Å proximity between C112 in neighboring apoE3 molecules in nHDL. Further, nHDL samples revealed a prominent peak at 385 nm (compared to 375 nm); this suggests that the pyrene moiety is located in a hydrophobic microenvironment, confirming lipid-association of apoE3. Fluorescence emission spectra of rHDL reconstituted with pyr-apoE3 and POPC (d) or POPC/cholesterol (e) are shown for comparison; the extent of excimer emission and 385 nm peak in these cases are comparable to that observed in nHDL samples.

Lipid-free pyr-apoEA277C(201–299) displays a dramatic excimer emission, Fig. 3B (a), as reported previously [12]; this is due to tetramerization mediated by the CT domain, which would align position 277 from four monomeric units [11,12] and bring 4 pyrene rings into close proximity. In nHDL bearing pyr-apoEA277C(201–299), a significant excimer emission peak was also noted (b), similar to that seen in the corresponding rHDL prepared with POPC/cholesterol (10:1 weight ratio) (c), Fig. 3B. This is indicative of juxtaposition of position 277 from neighboring molecules in lipid-associated apoEA277C(201–299).

To independently confirm the juxtaposition of apoE3 molecules in the lipid-associated state, nHDL (Mid fractions) bearing apoE3 was subjected to cross-linking using increasing molar concentrations of BMH, Fig. 4A. BMH is a homobifunctional agent that reacts predominantly with free thiols forming stable non-reducible thioether cross-links, and leading to dimeric proteins if the Cys are ~ 10 Å apart. The results obtained were compared with cross-linking carried out under similar conditions using rHDL, Fig. 4B. In both cases, a major band corresponding to dimeric apoE3 was noted (arrow). In addition, a minor band corresponding to ~ 130 kDa was noted, the reason for which is unclear since apoE3 has a single Cys. It may be due to cross-linking between amino groups on tan-




Fig. 4. Cross-linking of nHDL and rHDL. nHDL (A) or rHDL (B) bearing 1 µg unlabeled apoE3 was cross-linked as described under Section 2 by treatment with increasing concentrations of BMH as indicated. The samples were electrophoresed by SDS-PAGE under reducing conditions, and visualized by Western blot using apoE-HRP antibody. (C) rHDL bearing 10 µg unlabeled apoEA277C(201–299) was cross-linked as above, electrophoresed and visualized with Amido Black. Arrows draw attention to bands corresponding to cross-linked dimers of apoE3 or apoEA277C(201–299). (D) Possible models of apoE organization of nHDL. The circles represent location of single Cys.

dem apoE molecules leading to appearance of tetrameric species: although maleimide groups are ~ 1000 -fold more reactive with -SH than $-\text{NH}_3^+$ at pH 7.0, it is possible that BMH reacts with primary amines. A dimeric form was noted upon cross-linking in rHDL bearing POPC/cholesterol and apoEA277C(201–299) at all concentrations of BMH, Fig. 4C.

Our results show that J774 macrophages generate nHDL using exogenously added fluorescently-labeled apoE3 or apoEA277C(201–299) that can be examined by biophysical approaches. Where possible, we compared data obtained with nHDL with that from rHDL bearing the corresponding apoE. A direct comparison is not possible at this juncture since the apoE-containing nHDL generated herein are highly heterogeneous in terms of particle composition. This appears to be a characteristic feature of ABCA1-mediated nHDL biogenesis, as exemplified by studies carried out with apoA1 with different cell types: baby ham-




Fig. 3. Fluorescence emission spectra of nHDL- and rHDL-associated pyrene-labeled apoE. (A) Fluorescence emission spectra of pyr-apoE3 (~ 5 µg/ml protein) were recorded in lipid-free state (a), nHDL Top (b) and Mid (c) fractions, and rHDL-associated states with POPC (d) or POPC/cholesterol (e). (B) Fluorescence emission spectra of pyr-apoEA277C(201–299) were recorded in lipid-free state (a), nHDL (b) and rHDL-associated states with POPC/cholesterol (c). The spectra shown are average of 4 scans (excitation at 345 nm) and normalized with respect to the peak at 375 nm.

ster kidney or HEK293 cells [19] expressing ABCA1. In general, for reasons not clearly understood at present, apoE3 appears to generate predominantly larger discoidal nHDL particles, a trend also noted in rHDL bearing POPC and apoE3. In contrast, apoA1 can give rise to both small and large particles with POPC [19]. Further, other labs have shown that in contrast to cells, which have the capability to incorporate large amounts of cholesterol in the phospholipid bilayer of discoidal HDL with apoA1, it is difficult to achieve rHDL particles containing >30 mol% cholesterol [19]. We made a similar observation with apoE3; J774 cells were able to generate apoE3-containing nHDL with 1:1 phospholipid: cholesterol, while the reconstitution procedure yields rHDL with 10:1 ratio under the conditions employed herein, regardless of the initial ratio of phospholipid: cholesterol used in reconstitution protocol (2:1 to 1:10) (data not shown).

ApoE3 undergoes a conformational change upon lipid association, wherein the C-terminal domain unfurls away from the N-terminal domain, and the N-terminal 4-helix bundle undergoes opening with the helices moving apart from each other. Our current results with rHDL suggest a similar conformational re-organization of apoE3 upon interaction with POPC or POPC/cholesterol. This would allow the hydrophobic sides of the amphipathic helices to face the lipid environment to yield a stable lipoprotein complex. The helices of apoE3 appear to circumscribe the periphery like a belt around a bilayer of phospholipid (and cholesterol) molecules (~40 Å high) to form a discoidal lipoprotein complex.

Further, we propose a similar conformational re-organization of apoE3 in nHDL as well. The presence of an excimer peak in nHDL suggests that Cys112 from two neighboring molecules are juxtaposed, with the apoE3 molecules wrapped around the periphery of the lipid bilayer. The Cys-specific cross-linking data that show the formation of a dimer support this conclusion. The isolated C-terminal domain of apoE also appears to adopt a similar organization in nHDL and in rHDL with POPC/cholesterol.

During HDL biogenesis, the nHDL undergoes maturation to spherical HDL comprising a monolayer of amphipathic lipid and protein encompassing a core of CE. The conversion is catalyzed by lecithin-cholesterol acyltransferase (LCAT), which transfers a fatty acyl chain from phospholipid to cholesterol to form CE that transitions to the core. Since we did not detect any significant levels of CE in nHDL, and since the culture medium lacks LCAT, we believe that the nHDL generated herein is discoidal in geometry.

Given the particle heterogeneity, the precise number of apoE molecules per discoidal complex is not known at present. Based on particle mass and compositional analysis, we estimate that there would be 4–6 apoE3 molecules per particle. Regardless of the number, they appear to be organized as a parallel “in sync” or anti-parallel “out of sync” double belt circumscribing the periphery of discoidal nHDL, Fig. 4D. If apoE molecules are arranged in a perfectly anti-parallel manner (the N-terminal end of one molecule juxtaposed to the C-terminal end of the neighboring molecule), the distance between C112 in apoE3 (or A277C in apoE(201–299)) would be far >>10 Å and would not form an excimer or a cross-link; therefore the anti-parallel “in sync” and parallel “out of sync” (beyond 10 Å) orientation are excluded. Based on this data, we also exclude a helical “hairpin” conformation wherein a single apoE3 molecule folds on itself.

Taken together, the current data suggest that neighboring apoE3 molecules are arranged like a double belt in nHDL. Our study offers the opportunity to investigate the conformation of apolipoproteins in macrophage-assembled nHDL in fine detail using

rational design since it allows introduction of a spectroscopic probe of choice at any desired location on the protein.

Acknowledgments

This work was funded by NIH-GM105561, Maria Erlinda Co Sarino (SHK) and McAbee-Overstreet Graduate Research award (SK).

References

- [1] S.H. Zhang, R.L. Reddick, J.A. Piedrahita, et al., Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E, *Science* 258 (1992) 468–471.
- [2] G. Ghiselli, E.J. Schaefer, P. Gascon, et al., Type III hyperlipoproteinemia associated with apolipoprotein E deficiency, *Science* 214 (1981) 1239–1241.
- [3] G. Rudenko, J. Deisenhofer, The low-density lipoprotein receptor: ligands, debates and lore, *Curr. Opin. Struct. Biol.* 13 (2003) 683–689.
- [4] R.W. Mahley, S.C. Rall Jr., Apolipoprotein E: far more than a lipid transport protein, *Annu. Rev. Genom. Hum. Genet.* 1 (2000) 507–537.
- [5] S. Lund-Katz, M.C. Phillips, High density lipoprotein structure–function and role in reverse cholesterol transport, *Subcell. Biochem.* 51 (2010) 183–227.
- [6] A. von Eckardstein, J.R. Nofer, G. Assmann, High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport, *Arterioscler. Thromb. Vasc. Biol.* 21 (2001) 13–27.
- [7] R.W. Mahley, Y. Huang, K.H. Weisgraber, Putting cholesterol in its place: apoE and reverse cholesterol transport, *J. Clin. Invest.* 116 (2006) 1226–1229.
- [8] S. Yokoyama, ABCA1 and biogenesis of HDL, *J. Atheroscler. Thromb.* 13 (2006) 1–15.
- [9] D.M. Hatters, C.A. Peters-Libeu, K.H. Weisgraber, Apolipoprotein E structure: insights into function, *Trends Biochem. Sci.* 31 (2006) 445–454.
- [10] C. Wilson, M.R. Wardell, K.H. Weisgraber, et al., Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E, *Science* 252 (1991) 1817–1822.
- [11] J.A. Westerlund, K.H. Weisgraber, Discrete carboxyl-terminal segments of apolipoprotein E mediate lipoprotein association and protein oligomerization, *J. Biol. Chem.* 268 (1993) 15745–15750.
- [12] A.B. Patel, P. Khumsupan, V. Narayanaswami, Pyrene fluorescence analysis offers new insights into the conformation of the lipoprotein-binding domain of human apolipoprotein E, *Biochemistry* 49 (2010) 1766–1775.
- [13] H. Li, D.S. Lyles, M.J. Thomas, et al., Structural determination of lipid-bound ApoA-I using fluorescence resonance energy transfer, *J. Biol. Chem.* 275 (2000) 37048–37054.
- [14] W.S. Davidson, G.M. Hilliard, The spatial organization of apolipoprotein A-I on the edge of discoidal high density lipoprotein particles: a mass spectrometry study, *J. Biol. Chem.* 278 (2003) 27199–27207.
- [15] V. Narayanaswami, R.S. Kiss, P.M. Weers, The helix bundle: a reversible lipid binding motif, *Comp. Biochem. Physiol. Part A* 155 (2010) 123–133.
- [16] V. Narayanaswami, S.S. Szeto, R.O. Ryan, Lipid association-induced N- and C-terminal domain reorganization in human apolipoprotein E3, *J. Biol. Chem.* 276 (2001) 37853–37860.
- [17] V. Narayanaswami, J.N. Maiorano, P. Dhanasekaran, et al., Helix orientation of the functional domains in apolipoprotein E in discoidal high density lipoprotein particles, *J. Biol. Chem.* 279 (2004) 14273–14279.
- [18] V. Raussens, C.A. Fisher, E. Goormaghtigh, et al., The low density lipoprotein receptor active conformation of apolipoprotein E. Helix organization in N-terminal domain-phospholipid disc particles, *J. Biol. Chem.* 273 (1998) 25825–25830.
- [19] S. Lund-Katz, N.N. Lyssenko, M. Nickel, et al., Mechanisms responsible for the compositional heterogeneity of nascent high density lipoprotein, *J. Biol. Chem.* 288 (2013) 23150–23160.
- [20] G.K. Bains, S.H. Kim, E.J. Sorin, et al., The extent of pyrene excimer fluorescence emission is a reflector of distance and flexibility: analysis of the segment linking the LDL receptor-binding and tetramerization domains of apolipoprotein E3, *Biochemistry* 51 (2012) 6207–6219.
- [21] C. Vedhachalam, V. Narayanaswami, N. Neto, et al., The C-terminal lipid-binding domain of apolipoprotein E is a highly efficient mediator of ABCA1-dependent cholesterol efflux that promotes the assembly of high-density lipoproteins, *Biochemistry* 46 (2007) 2583–2593.
- [22] J.K. Bielicki, H. Zhang, Y. Cortez, et al., A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice, *J. Lipid Res.* 51 (2010) 1496–1503.
- [23] S. Tamamizu-Kato, J.K. Cohen, C.B. Drake, et al., Interaction with amyloid beta peptide compromises the lipid binding function of apolipoprotein E, *Biochemistry* 47 (2008) 5225–5234.
- [24] D.C. Dong, M.A. Winnik, The Py scale of solvent polarities, *Can. J. Chem.* 62 (1984) 2560–2565.
- [25] D.S. Karpovich, G.J. Blanchard, Relating the polarity-dependent fluorescence response of pyrene to vibronic coupling. Achieving a fundamental understanding of the py polarity scale, *J. Phys. Chem.* 99 (1995) 3951–3958.